1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Anterogen Co., Ltd.

Anterogen Co., Ltd.

KKRX:065660
13,820.00
KRW
-280.00
(-1.99%)
-161.67EPS
210.63BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
282.47
545.2
658.68
683.55
427.57
481.34
456.39
864.96
680.59
668.14
713.6
757.02
836.73
Basic EPS, GAAP
-218
-9
50
57
-114
-470
-481
-59
-706
-292
-236
-138
-161.67
Free Cash Flow per Basic Share
-272.95
28.63
-832.71
-125.1
-772.47
-541.59
-1,116.05
-701.31
-356.89
-225.26
-120.63
-129.13
-144.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,922.28
2,467.85
4,558.74
5,859.75
6,643.88
7,888.83
8,914.8
12,403.79
10,973.93
13,301.82
11,325.39
8,739.31
8,035.98
Tangible Book Value per Share
1,609.11
2,121.44
4,153.34
5,643.24
6,284.12
7,786.99
8,821.43
12,330.53
10,332.56
12,679.44
10,708.86
8,130.53
7,420.9
Basic Weighted Avg Shares
6
6
7
8
8
9
9
9
10
10
10
10
10
Sales/Revenue/Turnover
1,834
3,532
4,896
5,357
3,607
4,148
4,151
8,122
6,591
6,500
6,933
7,536
8,369
Operating Margin (%)
-86.45
-3.42
2.47
-1.79
-67.73
-70.11
-89.46
-32.31
-70.52
-78.06
-54.09
-32.28
-29.4
Depreciation Expense
264
292
311
391
589
597
616
827
763
830
586
594
582
Net Income, GAAP
-1,416
-58
372
447
-962
-4,050
-4,375
-554
-6,837
-2,841
-2,293
-1,374
-1,617
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-77.18
-1.65
7.59
8.34
-26.66
-97.64
-105.39
-6.82
-103.73
-43.7
-33.07
-18.23
-19.32
Working Capital
9,153
12,609
24,737
31,247
26,083
39,140
43,221
51,641
47,412
45,622
43,593
47,634
46,820
LT Debt
- -
- -
- -
4,195
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
12,961
16,639
34,024
46,606
56,073
68,394
81,067
116,867
106,791
129,445
110,212
87,446
80,409
Return on Invested Capital (%)
- -
- -
0.48
-0.21
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
1.47
1.13
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-0.39
1.47
1.11
-1.87
-6.52
-5.86
-0.56
-6.11
-2.41
-1.91
-1.39
-1.89

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
468,786
429,762
210,628

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
48,252
47,530
48,796
Cash, Cash Equivalents & STI
43,585
42,682
42,685
Accounts Receivable, Net
2,421
2,492
2,657
Inventories
1,110
1,166
2,344
Total Current Liabilities
618
750
1,976
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.35%
4.25%
-20.66%
Free Cash Flow
-302.34%
-31.21%
9.69%
Net Income, GAAP
22.56%
185.8%
-40.08%
Sales/Revenue/Turnover
12.12%
18.16%
8.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,533
1,710
1,903
1,788
6,933
2025
1,603
1,888
2,043
2,003
7,536
2026
2,123
2,200
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-59
-53
-17
-107.12
-236
2025
-71
-9
-7.93
-50.53
-138
2026
-88.17
-15
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seong-Gu Lee
Full Time Employees
32
Sector
Health technology
Industry
Biotechnology
Address
Namsung Plaza Seoul SL South Korea 08589
IPO Date
Feb 16, 2016
Website
anterogen.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Anterogen Co., Ltd. specializes in the development, manufacturing, and commercialization of cell therapy products primarily based on adipose-derived stem cells. Its main products include Cupistem injection for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction product used for regeneration of subcutaneous adipose tissue; and Remodulin injection for pulmonary arterial hypertension. The company also offers cosmetic products and raw materials such as SCM2, SCM2-Black hair care lines, and Therastem Derma and Therastem White skin care products. Founded in 2000 and headquartered in South Korea, Anterogen operates domestically and internationally in the biotechnology and pharmaceutical sectors. In recent developments, Anterogen has advanced clinical trials of its ALLO-ASC-BI and ANTG-ASC products targeting burn injury and complex fistula treatments. The firm has been actively involved in strategic partnerships, including licensing out Cupistem technology for Crohn's fistula treatment to Nihon Pharma in Japan, signaling its intent to expand its global footprint. The company has shown steady revenue growth, reporting 6.93 billion KRW in 2024 with a 6.65% year-over-year increase, while managing its cash flow and investments prudently amid increased R&D expenditure focused on innovative stem cell therapies. Anterogen’s business segments span pharmaceuticals, regenerative medicine, and cosmetics, leveraging stem cell technology as their core platform. The company has strengthened its pipeline with multiple ongoing clinical trials to support product commercialization and growth. These initiatives position Anterogen as a key player in the regenerative medicine industry within South Korea and the broader Asian markets, with a strategic emphasis on biopharmaceutical innovation and international collaboration.